PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
1.41
+0.19 (+15.57%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.22
Open0.00
Bid1.34 x 0
Ask1.41 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume82,226
Market Cap6.645M
Beta1.05
PE Ratio (TTM)N/A
EPS (TTM)-0.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-03-08
1y Target EstN/A
  • Newsfile20 hours ago

    Canntab Exceeds All-Time High Trading Prices and Grants Options

    Toronto, Ontario--(Newsfile Corp. - September 19, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.25 and $1.22, respectively, on the Canadian Securities Exchange (the "CSE"). This constitutes a 25% and 22% premium on the price of the ...

  • Newsfile2 days ago

    Canntab Signs Collaboration and Profit Sharing Agreement with FSD Pharma for Production and Market of Oral Dose Delivery Platforms

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement) (OTC Pink: FSDDF) (FRA: 0K9) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma ...

  • Newsfile2 days ago

    Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, "Emblem"). Dissolution testing conducted by ...

  • Newsfile9 days ago

    Canntab Therapeutics Launches Capital Markets Communications Strategy

    Toronto, Ontario--(Newsfile Corp. - September 11, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that, effective today, the Company will be increasing its level of engagement with shareholders and with potential retail and institutional investors. Accordingly, it has retained the services of Mackie Research Capital Corporation ("Mackie Research") to act as financial advisor to the Company and the services of Hybrid Financial Limited ("Hybrid") to assist the ...

  • CNW Group2 months ago

    Canntab Engages Industry Leader Lorne Gertner as Consultant

    TORONTO, July 16, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that it has engaged Lorne Gertner, one of the world's foremost investors in the cannabis industry and one of its trailblazing pioneers, as a strategic consultant.  Mr. Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding of retail distribution, both of which Canntab hopes to leverage as it positions itself for expansion into international markets. Mr. Gertner is a serial entrepreneur with experience in start-ups, IPOs, fashion, retail, architecture, real estate, and finance.

  • Newsfile2 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI with FSD Pharma to Obtain License to Process and Sell Cannabis Based Products - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - Canntab Therapeutics (CSE: PILL), a cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has entered into a non-binding letter of intent with FSD Pharma Inc. (CSE:HUGE). FSD Pharma, through its wholly-owned subsidiary FV Pharma, is a licensed producer under the Access to Cannabis for Medical Purposes Regulations.InvestmentPitch Media has produced a "video" which provides ...

  • CNW Group2 months ago

    Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms

    TORONTO, July 9, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab"), a leader in the rapidly growing cannabis pill market, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with FSD Pharma Inc. (CSE:HUGE) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction"). FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the "Canntab Premises").

  • Canntab Announces Launch of Innovative Hemp Oil Capsules
    Newsfile3 months ago

    Canntab Announces Launch of Innovative Hemp Oil Capsules

    Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the Health Canada approval and launch of the first of its '420 Therapeutics' brand of Cannabis wellness products: Hemp Oil Gel Capsules. Made from purified organic hemp seed oil, the Hemp Oil Gel Capsules are an easy and convenient way to enjoy the health benefits of hemp oil.Each Hemp Oil Gel Capsule contains ...

  • Newsfile3 months ago

    Canntab Announces Director Resignation

    Toronto, Ontario--(Newsfile Corp. - June 14, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") announces that Sheldon Inwentash has resigned from the Company's Board of Directors to pursue other opportunities. Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, "I would like to thank Sheldon for his valuable contributions to the Company and, on behalf of the Board, I wish him every success in his future endeavours."About CanntabCanntab Therapeutics Limited is ...

  • Newsfile4 months ago

    Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis

    Toronto, Ontario--(Newsfile Corp. - May 25, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 2 additional Canadian patent applications. Canntab's portfolio now includes 13 patent applications in Canada, the United States and internationally. These filings build on Canntab's growing intellectual property portfolio, which already included patent applications and ...

  • Newsfile4 months ago

    Canntab Appoints Bob Woloschuk to Advisory Board

    Toronto, Ontario--(Newsfile Corp. - May 17, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the appointment of Bob Woloschuk to its Advisory Board. Bob has over 20 years of pharmaceutical executive experience and has a keen eye for licensing opportunities, both in Canada and in international markets.Jeff Renwick, Chief Executive Officer and a Director, commented "We are grateful for the opportunity to add someone of Bob's calibre ...

  • Newsfile4 months ago

    Canntab Provides Clarification on CFN Media Engagement

    Toronto, Ontario--(Newsfile Corp. - May 15, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") wishes to provide clarification on the terms of its engagement of CFN Media Group ("CFN Media"), which were previously announced in a news release disseminated by CFN Media on May 15, 2018. Canntab wishes to clarify that CFN Media was engaged to provide investor relations services. The terms of the engagement require Canntab to pay CFN Media ...

  • Newsfile4 months ago

    Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

    Paris, Ontario--(Newsfile Corp. - May 14, 2018) - Emblem Corp. (TSXV: EMC) (TSXV: EMC.WT) ("Emblem" or the "Company") and Canntab Therapeutics Limited (CSE: PILL) ("Canntab") are pleased announce to receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the "Sustained Release Product" or the "Product"), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab's partnership to develop long-acting cannabis formulations. ...

  • Newsfile5 months ago

    CSE New Listing - Canntab Therapeutics Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - April 27, 2018) - Canntab Therapeutics (CSE: PILL) is one of the latest new listings on the Canadian Securities Exchange. Markham, Ontario-based Canntab is a Canadian cannabis oral dosage formulation company, en-gaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. InvestmentPitch Media has produced a "video" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and ...